RCS - Novacyt S.A. - London Vet Show: Launch of animal multiplex assays

Novacyt SAAnnouncement

14/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241114:nRSN1470Ma&default-theme=true

RNS Number : 1470M  Novacyt S.A.  14 November 2024

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Launch of new animal multiplex assays at London Vet Show

Rapid, accurate detection of six gastrointestinal disease-causing pathogens in
cats and dogs

 

Paris, France, Eastleigh and Manchester, UK - 14 November 2024
- Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular
diagnostics company with a broad portfolio of integrated technologies and
services, announces that it is launching two new assays for gastrointestinal
disease in dogs and cats at the London Vet Show, held from 14-15 November
2024.

 

The genesig®PLEX kits for Canine and Feline Gastrointestinal (GI) Diseases
are multiplexed qPCR assays that detect six disease-causing pathogens in the
digestive system of cats and dogs in a two-tube assay, delivering a
streamlined and efficient testing solution for centralised veterinary
laboratories. Each target has been carefully selected to detect a key pathogen
that can cause potentially serious or life-threatening GI illnesses in cats
and dogs.

 

Testing for six pathogens using one sample will reduce hands-on time for
laboratory technicians as well as the use of consumables. The kits provide
results in less than three hours, enabling quicker, more comprehensive results
to the veterinarian and ensuring faster treatment for the family pet.

 

If you are attending the London Vet Show and would like further information on
the new genesig®PLEX kits for Canine and Feline Gastrointestinal (GI)
Diseases, or Novacyt's wider portfolio of veterinary assays, the Novacyt team
can be found at Booth No A49.

 

Lyn Rees, CEO of Novacyt, said: "Following consultation with our customers and
further market research, we saw clear demand in the veterinary industry for
multiplex assays that target several companion animal pathogens using a single
sample. With the launch of our two new genesig®PLEX kits for cats and dogs,
we are making testing for these gastrointestinal pathogens more
cost-effective, faster and less hands-on for laboratories, and enabling
quicker results for veterinarians.

 

"Adding to the 200+ veterinary assays in Primer Design's existing portfolio,
these tests demonstrate our continued commitment to identifying emerging
diagnostic needs and providing best-in-class solutions for our customers."

 

Contacts

 

 Novacyt SA                                                              https://novacyt.com/investors (https://novacyt.com/investors/)
 Lyn Rees, Chief Executive Officer                                        Via Walbrook PR
 Steve Gibson, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                                    +44 (0)20 3470 0470
 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Deutsche Numis (Joint Broker)                                                                                    +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Michael Palser

 Allegra Finance (French Listing Sponsor)       +33 (1) 42 22 10 10

                                             r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                 y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                                         +44 (0)20 7933 8780 or novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 Paul McManus / Lianne Applegarth                                        +44 (0)7980 541 893 / +44 (0)7584 391 303

 Phillip Marriage / Alice Woodings                                        +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily focused on the
delivery of genomic medicine. The Company develops, manufactures, and
commercialises a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions from sample
to result across multiple sectors including human health, animal health and
environmental.

 

The Company is divided into three business segments:

 

 Clinical             Broad portfolio of human clinical in vitro diagnostic products, workflows and
                      services focused on three therapeutic areas:

                      ·    Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy
                      tests

                      ·    Precision Medicine: DPYD genotyping assay

                      ·    Infectious Diseases: Winterplex, multiplex winter respiratory PCR
                      panel

 Instrumentation      Portfolio of next generation size selection DNA sample preparation platforms
                      and rapid PCR machines, including:

                      ·    Ranger® Technology: automated DNA sample preparation and target
                      enrichment technology

                      ·    genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

 Research Use Only    Range of services for the life sciences industry:

                      ·    Design, manufacture, and supply of high-performance qPCR assays and
                      workflows for use in human health, agriculture, veterinary and environmental,
                      to support global health organisations and the research industry

                      ·    Pharmaceutical research services: whole genome sequencing (WGS) /
                      whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the
UK (in Eastleigh and Manchester), Singapore, the US and Canada and has a
commercial presence in over 65 countries. The Company is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext
Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

About the London Vet Show

 

The London Vet Show is Europe's largest veterinary conference and exhibition.
Run with education partners the Royal Veterinary College and British
Veterinary Association, the London Vet Show brings together thousands of
veterinary professionals, innovators and industry giants, with over
400 exhibitors and 200 speakers.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKNBPABDDKDD